ArticleCureus2025
Adaptation of Axillary Reverse Mapping Using Methylene Blue Dye for the Prevention of Post-Mastectomy Lymphedema: A Low-Cost Alternative to Radiotracers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPost-mastectomy lymphedema is a common complication of axillary lymph node dissection (ALND). Axillary reverse mapping (ARM) aims to preserve arm lymphatics and reduce lymphedema. Radiotracer-based ARM is costly and limited in availability, whereas methylene blue dye offers a potentially low-cost alternative. The objective of this study was to evaluate the feasibility, safety, and short-term association of methylene blue-based ARM with post-mastectomy lymphedema. MATERIALS AND
methodsThis prospective observational study included 60 female patients undergoing mastectomy with ALND at Ziauddin Hospital over 6 months. ARM lymphatics were identified and preserved using methylene blue dye when oncologically safe. Patients were followed for 6 months; lymphedema was assessed by clinical examination and measurements of arm circumference at standardized landmarks. Statistical analyses included the Chi-square test, the independent t-test, and exploratory multivariate logistic regression adjusting for age, BMI, tumor stage, and number of lymph nodes removed.
resultsARM lymphatics were identified in 51 (85.0%) patients and preserved in 46 (90.2%). Lymphedema occurred in 2 (4.3%) patients in the ARM-preserved group versus 4 (28.6%) in the sacrificed/not-identified group (χ² = 6.37, p = 0.012). Mean arm circumference increase at 6 months was 0.7 ± 0.5 cm versus 1.6 ± 0.7 cm (t = 4.81, p < 0.001). In exploratory multivariate analysis, ARM preservation was associated with lower odds of lymphedema (adjusted OR = 0.21, 95% CI: 0.05-0.88, p = 0.032). No major adverse events were observed; however, given the limited sample size and non-systematic adverse-event monitoring, rare reactions cannot be excluded.
conclusionMethylene blue-based ARM is feasible and associated with lower lymphedema incidence and reduced arm swelling in this cohort. Findings should be interpreted cautiously due to the observational design, small sample size, short follow-up, and limited safety monitoring. These results indicate an association rather than established causal effectiveness and suggest that methylene blue may be a practical alternative to radiotracers in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.